pf-00489791
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00422461)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 5AINHIBITOR
Phosphodiesterase 5A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21- Mol. weight
- 476.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4210847 ↗
Also known as
- pf-00489791
- pf-00489791
- pf-00489791
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02319148 | Phase 1 | Jul 1, 2014 | Pfizer |
| NCT01200394 | Phase 2 | Oct 1, 2010 | Pfizer |
| NCT01090492 | Phase 2 | Aug 1, 2010 | Pfizer |
| NCT00853112 | Phase 2 | Apr 1, 2009 | Pfizer |
| NCT00422461 | Phase 2 | Feb 1, 2007 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 5 | 5 | 2 | 2007 |
1 organizations
Page 1 / 1